PTable S5 Markers of each cell cluster. by Li-Hong Chen (610826)

Subjects:

Effects of clonal integration and <i>Bacillus subtilis</i> on total mass (A, E, I), leaf biomass (B, F, J), stolon biomass (C, G, K), and root biomass (D, H, L) of the basal, apica... by Bing-Nan Zhao (21553401)

Subjects:

A schematic overview of the bioinformatic tools conducted in this study. by Zeynab Hosseinpoor (19762319)

Subjects:

Schema of the reflexology circuit and the stimulated reflex zones. a. by Karel Joineau (21799908)

Subjects:

The spheroid assay is used to assess long-term effects of therapy on tumor cell by culturing the tumor cells in a micro-mass, which is a 3D tumor mass used as a surrogate for in vi... by Bryan S. Margulies (21492667)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Fig 3 - by Razieh Bidhendi-Yarandi (7139387)

Subjects:

2D and 3D AFM micrographs of fabricated samples (a) 5LZCM (b) 10LZCM (c) 15LZCM. by Md. Abu Daud (21485629)

Subjects:

Illumination distributions (a-c) and variations in illuminance values along the <i>x</i>-axis (d-f) of the RVL at different angles. by Fei Li (143236)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”